Goldman Sachs sets USD 441 target for Krystal Biotech stock

Published on 10/07/2026 at 00:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 119.22 million, and diluted EPS was USD 1.79. Krystal Biotech stock had a EUR 290.25 prior close on October 5, 2026.

KRYS, US5011471027, Illustration mit AI erstellt.

Goldman Sachs set a USD 441.00 price target for Krystal Biotech stock on September 24, 2026, when analyst Andrea Newkirk resumed coverage with a Buy rating. The target places the analyst view above the company's recent US market quotation and makes pipeline execution the key valuation question.

Goldman sees pipeline value

As Markets Insider reported on September 24, 2026, Goldman highlighted Krystal's commercial execution and pipeline optionality. The company markets VYJUVEK for dystrophic epidermolysis bullosa and is developing additional genetic medicines through its redosable HSV vector platform, according to Krystal Biotech.

The target is a named analyst action rather than a company forecast. That distinction matters because the latest reported quarter also contained a measurable revenue counterpoint.

Revenue growth meets an earnings beat

For the second quarter of 2026, revenue was USD 119.22 million and diluted earnings per share was USD 1.79. Investing.com reported that earnings per share exceeded the USD 1.70 consensus, while revenue came in below the USD 122.30 million estimate.

The comparison shows why the Goldman thesis depends on more than quarterly earnings: the USD 0.09 earnings-per-share beat was paired with a USD 3.08 million revenue shortfall. Krystal's gross margin was 95.00 percent in the same quarter, giving the commercial business substantial operating leverage if product demand expands.

Stock remains below yearly high

Krystal Biotech had a market capitalization of USD 9.6 billion and a 52-week range of USD 179.19 to USD 382.54 as of October 6, 2026. Its prior close at Lang & Schwarz was EUR 290.25 for October 5, 2026, while the data set carried a quote timestamp of October 6, 2026 at 10:59 p.m. CEST.

MarketBeat lists November 2, 2026 as the scheduled date for Krystal's third-quarter results, with consensus revenue of USD 129.12 million and consensus earnings per share of USD 1.91. Those estimates set the next numerical test for the commercial rollout and the pipeline valuation behind the Goldman target.

Next results set the test

Krystal Biotech is listed on NASDAQ under ticker KRYS and operates in healthcare biotechnology. The company was trading within a USD 179.19 to USD 382.54 52-week range as of October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Krystal Biotech stock.